For example, a recent publication, Oh et al. 24 has found a low-expression of TP53 protein was associated with poor cancer-specific survival in Stage III and high-rick Stage II CRC patients (N = 621) who were treated with oxaliplatin-based adjuvant chemotherapy. This evidence concerns the gene TP53 and colorectal carcinoma.